Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
Income Statement Evolution (Annual data)
Fiscal Period: November | 2020 | 2021 |
---|---|---|
Net sales | - | - |
EBITDA | - | - |
EBIT 1 | -0.0257 | -0.462 |
Operating Margin | - | - |
Earnings before Tax (EBT) 1 | -0.0257 | -0.462 |
Net income 1 | -0.0257 | -0.462 |
Net margin | - | - |
EPS 2 | -0.000342 | -0.006160 |
Free Cash Flow | - | - |
FCF margin | - | - |
FCF Conversion (EBITDA) | - | - |
FCF Conversion (Net income) | - | - |
Dividend per Share | - | - |
Announcement Date | 22-03-15 | 22-03-15 |
Balance Sheet Analysis
Fiscal Period: November | 2020 | 2021 |
---|---|---|
Net Debt 1 | - | - |
Net Cash position 1 | 0 | - |
Leverage (Debt/EBITDA) | - | - |
Free Cash Flow | - | - |
ROE (net income / shareholders' equity) | - | 378% |
ROA (Net income/ Total Assets) | - | - |
Assets 1 | - | - |
Book Value Per Share 2 | -0 | -0 |
Cash Flow per Share 2 | - | - |
Capex | - | - |
Capex / Sales | - | - |
Announcement Date | 22-03-15 | 22-03-15 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-.--% | 531 | |
+11.78% | 2.97B | |
-46.69% | 1.87B | |
-1.63% | 1.31B | |
-3.01% | 1.03B | |
+28.03% | 658M | |
-23.08% | 428M | |
-11.16% | 329M | |
-13.66% | 322M | |
-3.90% | 317M |
- Stock Market
- Equities
- INSD Stock
- Financials Instadose Pharma Corp.